Using small RNA sequencing, investigators found miRNAs in the blood that track with cirrhosis, hepatitis, type 2 diabetes, or acetaminophen toxicity.
Called the Glyco Liver Profile, the test uses capillary electrophoresis to measure glycosylation of proteins to diagnosis and monitor chronic liver diseases.
The partners will develop biomarkers and assays to evaluate non-alcoholic steatohepatitis, a disease characterized by liver scarring due to inflammation.
Based on genetic patterns in thousands of individuals with primary sclerosing cholangitis, researchers identified four new risk loci and explored ties to IBD.
Pittsburgh-based Curable is building a coalition to sequence genomes of patients with a rare autoimmune disease of the bile ducts to inform drug development.
The CRISPR/Cas9 therapeutics firm could reap billions from the Regeneron collaboration, which includes $75 million up front and a $50 million private placement.
Researchers sequenced and analyzed the negative-sense RNA tilapia lake virus, implicated in large die-offs of farmed and wild tilapia in Israel and Ecuador.
In Nature this week: DNA-free genome editing in plants, new risk loci for atopic dermatitis, and more.
A two-stage genome-wide association study has linked new loci to alcohol-related cirrhosis risk and confirmed a previously identified one.
The company aims to validate two diagnostic algorithms based in part on microRNA biomarkers to identify patients with moderate-to-severe disease.
Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.
US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.
A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.
In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.